Adding immunotherapy to a targeted agent significantly improved progression-free survival (PFS) when compared with a targeted agent alone in the first-line treatment of advanced renal cell carcinoma (RCC), suggests interim results from the JAVELIN Renal 101 trial.
The combination therapy, comprised of the anti-programmed cell death ligand 1 (PD-L1) drug avelumab (Bavencio, EMD Serono) and the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) axitinib (Inlyta, Pfizer), was pitted against the current standard of care, sunitinib (Sutent, Pfizer).
The results, presented here at the European Society of Medical Oncology 2018 annual meeting, revealed that combination therapy improved median PFS by 39% in patients who tested positive for PD-L1 expression and by 31% in the overall patient population.
The objective response rate with avelumab plus axitinib was also almost more than twice that seen with sunitinib, and the combination therapy had a favorable safety profile.
Study presenter Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, said in an ESMO press release that “the findings support the potential of avelumab plus axitinib as a new treatment approach for patients with advanced RCC.”
As this was a preliminary analysis of the JAVELIN Renal 101 study, the overall survival data are immature, although there was a signal for an increase in median overall survival, at a hazard ratio at this point of 0.79 (P = .0679)
Commenting for ESMO, Thomas Powles, MD, PhD, consultant oncologist at Barts Health NHS Trust, London, UK, described the results as “eye-catching.”
Adding a note of caution, however, Powles added: “This approach involves giving combinations of most active agents upfront; therefore, there is uncertainty around whether this will translate into a similarly impressive survival signal as seen with other immunotherapy combinations.”
For All Patients?
“The combination benefit was shown in all subgroups of patients, by independent review as well as by investigators, and whether tumor cells stained positive for PD-L1 or not,” Motzer commented.
At a press conference for the study, Motzer said that, based on their findings, “I don’t believe you need to test [PD-L1] to choose patients for this therapy.”
“It may be that…the hazard ratio is a little better in the PD-L1+ group, but I don’t think it’s required to use this medicine. I think it can be given regardless of PD-L1 status,” he said.
–GDMeds, an India Pharmacy Service company
[Disclaimer]The Site is operated by GDMeds and all rights thereto are owned and reserved by GDMeds. The contents and works on these pages compiled by GDMeds are subject to copyright law. Copying, processing, distribution and any kind of use outside the limits of copyright law require the written consent of GDMeds In case the content is not created by GDMeds the copyrights of third parties are being observed. However, if a user becomes aware of a copyright infringement, GDMeds asks the user for notification. Upon notification of such violations, GDMeds will remove the content immediately.
[免责声明]本网站由印度极得美运营。印度极得美拥有和保留一切权利。印度极得美的网页内容及文档受版权法保护。复制、加工、传播及任何超出版权法限制的任何使用行为均必须得到印度极得美书面许可。如相关内容如非由印度极得美创作，需遵守第三方的版权，特别是标示为第三方内容的。如用户发现侵犯版权的行为，请通知极得美。一旦收到违反通知，极得美将立刻移除相关内容。
[отказ]Сайт управляется GDMeds, и все права на него принадлежат и зарезервированы GDMeds. Содержание и работы на этих страницах, составленные GDMeds, защищены законом об авторском праве. Копирование, обработка, распространение и любое использование вне пределов авторского права требуют письменного согласия GDMeds. Если контент не создан GDMeds, то соблюдаются авторские права третьих лиц. Однако, если пользователь узнает о нарушении авторских прав, GDMeds запрашивает у пользователя уведомление. После уведомления о таких нарушениях GDMeds немедленно удалит контент.